# HGLG11 Analysis üü¢
**Date:** 2026-01-27
**Sentiment:** Neutral (0.1)
**Trend:** Sideways

## üö® Key Events
- **Vacancy Increase** (Negative): Physical vacancy increased from 2.4% in November 2025 to a projected 4.5% in February 2026.
- **Tenant Exits** (Negative): Multiple tenant exits occurred between November 2025 and February 2026, including Roja, Eletrobras (Syslog), Memodoc (Duque de Caxias), Plastic Omnium (S√£o Jos√©), √äxito (Syslog), TLS (CLE), and RV Imola (Ribeir√£o Preto).
- **Tenant Acquisition** (Positive): Knight Therapeutics became a new tenant in Masterlabs in December 2025.
- **Monthly Dividend** (Neutral): Maintained monthly dividend of R$ 1.10 per share with ex-dates on January 2, 2026, and February 03, 2026, and payment dates on January 15, 2026, and February 13, 2026.
- **Asset Revaluation** (Positive): Real estate assets reevaluated in November 2025, resulting in an average increase of 2.52% compared to December 2024 accounting values.
- **Share Issuance** (Neutral): Completed the 10th share issuance, raising R$ 1.4 billion.

## üìù Detailed Summary
HGLG11's physical vacancy increased from 2.4% in November 2025 to a projected 4.5% in February 2026. Tenant exits included Roja, Eletrobras (Syslog), Memodoc (Duque de Caxias), Plastic Omnium (S√£o Jos√©), √äxito (Syslog), TLS (CLE), and RV Imola (Ribeir√£o Preto) between November 2025 and February 2026. Knight Therapeutics became a new tenant in Masterlabs in December 2025. The fund maintained a monthly dividend of R$ 1.10 per share (ex-dates January 2, 2026, and February 03, 2026). A November 2025 asset revaluation resulted in a 2.52% average increase compared to December 2024. The 10th share issuance was completed, raising R$ 1.4 billion. The dividend yield is approximately 8.69% annually.